4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-046731
Chief Accounting Officer sold 1,653 shares at $2.50 ($4,125)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-08-17 | Sale : show line 1 in the form 10b5-1 | −1,653 | $2.50 | $4,125 | 127,175 | D |
| Open-market sales · 1,653 sh · avg $2.50 · $4,125 | ||||||
Loading xslF345X05/doc4.xml…